TY  - GEN
AU  - Eggermont,Alexander M M
AU  - Blank,Christian U
AU  - Mandala,Mario
AU  - Long,Georgina V
AU  - Atkinson,Victoria
AU  - Dalle,Stéphane
AU  - Haydon,Andrew
AU  - Lichinitser,Mikhail
AU  - Khattak,Adnan
AU  - Carlino,Matteo S
AU  - Sandhu,Shahneen
AU  - Larkin,James
AU  - Puig,Susana
AU  - Ascierto,Paolo A
AU  - Rutkowski,Piotr
AU  - Schadendorf,Dirk
AU  - Koornstra,Rutger
AU  - Hernandez-Aya,Leonel
AU  - Maio,Michele
AU  - van den Eertwegh,Alfonsus J M
AU  - Grob,Jean-Jacques
AU  - Gutzmer,Ralf
AU  - Jamal,Rahima
AU  - Lorigan,Paul
AU  - Ibrahim,Nageatte
AU  - Marreaud,Sandrine
AU  - van Akkooi,Alexander C J
AU  - Suciu,Stefan
AU  - Robert,Caroline
TI  - Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
SN  - 1533-4406
PY  - 2018///0517
KW  - Adjuvants, Immunologic
KW  - adverse effects
KW  - Adult
KW  - Aged
KW  - Aged, 80 and over
KW  - Antibodies, Monoclonal, Humanized
KW  - B7-H1 Antigen
KW  - analysis
KW  - Disease-Free Survival
KW  - Double-Blind Method
KW  - Female
KW  - Humans
KW  - Infusions, Intravenous
KW  - Intention to Treat Analysis
KW  - Kaplan-Meier Estimate
KW  - Male
KW  - Melanoma
KW  - drug therapy
KW  - Middle Aged
KW  - Neoplasm Recurrence, Local
KW  - Neoplasm Staging
KW  - Quality of Life
KW  - Skin Neoplasms
KW  - Survival Rate
N1  - Publication Type: Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial
UR  - https://doi.org/10.1056/NEJMoa1802357
ER  -